Author

Ju-Whei Lee

Observed name: Ju Whei Lee

Institution: Dana-Farber Cancer Institute

Observed institution: Dana-Farber Cancer Institute

OpenAlex ID: A5111495609

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43–9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern Cooperative Oncology Group Study E2501

2012 · Heather A. Wakelee, Ju-Whei Lee, et al. · Journal of Thoracic Oncology · 55

Phase II 2‐arm trial of the proteasome inhibitor, PS‐341 (bortezomib) in combination with irinotecan or PS‐341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group

2012 · Jill Gilbert, Ju Whei Lee, et al. · Head & Neck · 41

Intracluster correlation coefficients from cluster randomized trials conducted within the NCI Community Oncology Research Program (NCORP)

2025 · Anna C Snavely, Heather J Gunn, et al. · JNCI Monographs · 3

Works count: 3

Citation count: 99

H-index: 3

I10-index: 2